Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Patrice Dosquet"'
Autor:
Régis Bordet, Jean-François Dartigues, Bruno Dubois, Jean-Marie Goehrs, Laura Vernoux, Franck Semah, Florence Pasquier, Claude Bidaut-Mazel, Zeina Antoun, Olivier Arnaud, Olivier Blin, Catherine Deguines, Philippe Derambure, Patrice Dosquet, Jean Pierre Duffet, Sylvia Goni, Philippe Gustovic, Marie Lang, Marie-Laure Laroche, Antoine Pariente, Jean-Jacques Pere, Odile Regnier, Philippe Truffinet
Publikováno v:
Therapies. 65:277-283
Resume Le developpement clinique de medicaments disease-modifiers dans la maladie d’Alzheimer se heurte a des difficultes methodologiques dont temoignent plusieurs echecs recents de medicaments en phase III. Compte-tenu des enjeux financiers inhere
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0143dd98c706bb29a21547b4c6c0f99b
https://doi.org/10.2515/therapie/2010039
https://doi.org/10.2515/therapie/2010039
Autor:
Patrice Dosquet, Jeremy M. Grimshaw, Sheldon Greenfield, Paul M. Schyve, Richard Grol, Peter A. Gross, Shan Cretin, Stephen C. Schoenbaum, Wilfred Lorenz, Charles D. Shaw, Gregg S. Meyer, Niek Klazinga, John Ferguson
Publikováno v:
The Joint Commission Journal on Quality Improvement. 26:547-553
Roundtable-at-a-Glance Background A roundtable held October 5–6 1999, in Maidstone, Kent, United Kingdom, was convened to identify current strategies and ongoing challenges in implementing evidence-based practice guidelines in health care. Despite
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6df2b3358b2a0997b8a1dd79cd3c616b
https://doi.org/10.1016/s1070-3241(00)26046-x
https://doi.org/10.1016/s1070-3241(00)26046-x
Publikováno v:
Orphanet Journal of Rare Diseases
From 6th European Conference on Rare Diseases and Orphan Products
From 6th European Conference on Rare Diseases and Orphan Products, May 2012, Brussels, Belgium. pp.A12
From 6th European Conference on Rare Diseases and Orphan Products
From 6th European Conference on Rare Diseases and Orphan Products, May 2012, Brussels, Belgium. pp.A12
Guidelines are systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances[1]. They concern often complex diagnostic or therapeutic strategies with several possibl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aac40019112d89392b586cd4eb023cfa
https://www.hal.inserm.fr/inserm-00756021
https://www.hal.inserm.fr/inserm-00756021
Autor:
Régis Bordet, Jean-François Dartigues, Bruno Dubois, Jean-Marie Goehrs, Laura Vernoux, Franck Semah, Florence Pasquier, Claude Bidaut-Mazel, Zeina Antoun, Olivier Arnaud, Olivier Blin, Antoine Coquerel, Catherine Deguines, Philippe Derambure, Patrice Dosquet, Jean-Pierre Duffet, Sylvia Goni, Philippe Gustovic, Marie Lang, Marie-Laure Laroche, Antoine Pariente, Jean-Jacques Pere, Odile Regnier, Philippe Truffinet
Publikováno v:
Therapie. 65(4)
As the failure of several recent Phase III drug development programmes bears witness, the clinical development of “disease-modifying” drugs in Alzheimer’s disease has been confronted with challenging methodological difficulties. Taking into acc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d59afa840e517b81a8ffd59acd350f1
https://pubmed.ncbi.nlm.nih.gov/20854749
https://pubmed.ncbi.nlm.nih.gov/20854749